JP2019515920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515920A5 JP2019515920A5 JP2018555672A JP2018555672A JP2019515920A5 JP 2019515920 A5 JP2019515920 A5 JP 2019515920A5 JP 2018555672 A JP2018555672 A JP 2018555672A JP 2018555672 A JP2018555672 A JP 2018555672A JP 2019515920 A5 JP2019515920 A5 JP 2019515920A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- composition
- injury
- agonist
- stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 26
- 230000009529 traumatic brain injury Effects 0.000 claims description 26
- 208000027418 Wounds and injury Diseases 0.000 claims description 24
- 239000000556 agonist Substances 0.000 claims description 24
- 230000006378 damage Effects 0.000 claims description 24
- 208000014674 injury Diseases 0.000 claims description 24
- 208000006011 Stroke Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 230000001404 mediated effect Effects 0.000 claims description 18
- 208000010125 myocardial infarction Diseases 0.000 claims description 13
- 208000031225 myocardial ischemia Diseases 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 208000018737 Parkinson disease Diseases 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000000626 neurodegenerative effect Effects 0.000 claims description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
- 208000023105 Huntington disease Diseases 0.000 claims description 9
- 208000029028 brain injury Diseases 0.000 claims description 9
- 208000019622 heart disease Diseases 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 8
- 208000019695 Migraine disease Diseases 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 208000017004 dementia pugilistica Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 230000008439 repair process Effects 0.000 claims description 8
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 7
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 claims description 6
- 102000009346 Adenosine receptors Human genes 0.000 claims description 5
- 108050000203 Adenosine receptors Proteins 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000004112 neuroprotection Effects 0.000 claims description 5
- 230000000324 neuroprotective effect Effects 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000013883 Blast injury Diseases 0.000 claims description 4
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims description 4
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims description 4
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 201000007930 alcohol dependence Diseases 0.000 claims description 4
- 230000003491 cAMP production Effects 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 230000009514 concussion Effects 0.000 claims description 4
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 4
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 230000005961 cardioprotection Effects 0.000 claims description 3
- 210000005003 heart tissue Anatomy 0.000 claims description 3
- 230000004224 protection Effects 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 102000016924 KATP Channels Human genes 0.000 claims description 2
- 108010053914 KATP Channels Proteins 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 102000000072 beta-Arrestins Human genes 0.000 claims description 2
- 108010080367 beta-Arrestins Proteins 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 2
- 239000004031 partial agonist Substances 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 206010011878 Deafness Diseases 0.000 claims 2
- 230000006399 behavior Effects 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 2
- 231100000874 brain damage Toxicity 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010010144 Completed suicide Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010013887 Dysarthria Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010021030 Hypomania Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010027603 Migraine headaches Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000003293 cardioprotective effect Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000032625 disorder of ear Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 230000004973 motor coordination Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 7
- -1 MRS2690 Chemical compound 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 4
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 4
- 229940045145 uridine Drugs 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 description 2
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 2
- XCCTYIAWTASOJW-UHFFFAOYSA-N UDP-Glc Natural products OC1C(O)C(COP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-UHFFFAOYSA-N 0.000 description 2
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 2
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 2
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 2
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 2
- GAYWHRPOIWFKIF-DDDALXFXSA-N (1s,2r,3s,4r,5s)-4-[2-chloro-6-[(3-chlorophenyl)methylamino]purin-9-yl]-2,3-dihydroxy-n-methylbicyclo[3.1.0]hexane-1-carboxamide Chemical compound N1=C(Cl)N=C2N([C@@H]3[C@H]4C[C@]4([C@H]([C@H]3O)O)C(=O)NC)C=NC2=C1NCC1=CC=CC(Cl)=C1 GAYWHRPOIWFKIF-DDDALXFXSA-N 0.000 description 1
- LYLLLJJYBWLGHW-CIZVZKTGSA-N (1s,2r,3s,4r,5s)-4-[6-[(3-chlorophenyl)methylamino]-2-[2-(3,4-difluorophenyl)ethynyl]purin-9-yl]-2,3-dihydroxy-n-methylbicyclo[3.1.0]hexane-1-carboxamide Chemical compound N1=C(C#CC=2C=C(F)C(F)=CC=2)N=C2N([C@@H]3[C@H]4C[C@]4([C@H]([C@H]3O)O)C(=O)NC)C=NC2=C1NCC1=CC=CC(Cl)=C1 LYLLLJJYBWLGHW-CIZVZKTGSA-N 0.000 description 1
- KOCIMZNSNPOGOP-IWCJZZDYSA-N (2r,3r,4s,5r)-2-[2-hex-1-ynyl-6-(methylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(C#CCCCC)=NC(NC)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KOCIMZNSNPOGOP-IWCJZZDYSA-N 0.000 description 1
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- KXDJDMIUJGBFAV-QYUDBREXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[(3-methyl-1,2-oxazol-5-yl)oxymethyl]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)COC=3ON=C(C)C=3)=C2N=C1 KXDJDMIUJGBFAV-QYUDBREXSA-N 0.000 description 1
- FOUQIXNUUYCGAU-MOROJQBDSA-N (2s,3s,4r,5r)-5-(1,3-dibutyl-2,6-dioxopurin-7-yl)-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound C1=2C(=O)N(CCCC)C(=O)N(CCCC)C=2N=CN1[C@@H]1O[C@H](C(=O)NC)[C@@H](O)[C@H]1O FOUQIXNUUYCGAU-MOROJQBDSA-N 0.000 description 1
- FDEACFAXFCKCHZ-MOROJQBDSA-N (2s,3s,4r,5r)-5-(6-amino-2-hex-1-ynylpurin-9-yl)-n-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C12=NC(C#CCCCC)=NC(N)=C2N=CN1[C@@H]1O[C@H](C(=O)NCC)[C@@H](O)[C@H]1O FDEACFAXFCKCHZ-MOROJQBDSA-N 0.000 description 1
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 description 1
- IRIUFVPPSHYZRM-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methylthiolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)S[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IRIUFVPPSHYZRM-PFHKOEEOSA-N 0.000 description 1
- SWXXHYTUMIMRFO-KSVNGYGVSA-N (2s,3s,4r,5r)-5-[6-amino-2-(2-phenylethynyl)purin-9-yl]-n-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(C#CC=3C=CC=CC=3)=NC(N)=C2N=C1 SWXXHYTUMIMRFO-KSVNGYGVSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- CYQQUPOETXXUCK-CSTWGOEFSA-N 6-[2-chloro-6-[[[9-[(1S,2R,3S,4R,5S)-3,4-dihydroxy-5-(methylcarbamoyl)-2-bicyclo[3.1.0]hexanyl]purin-6-yl]amino]methyl]phenyl]hex-5-ynoic acid Chemical compound CNC(=O)[C@@]12C[C@@H]1[C@H]([C@H](O)[C@@H]2O)n1cnc2c(NCc3cccc(Cl)c3C#CCCCC(O)=O)ncnc12 CYQQUPOETXXUCK-CSTWGOEFSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 108091023231 Ap4A Proteins 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- DJUSWOSTDQSFPL-NQALCROSSA-N C[C@](CO)(CC([C@@H]1O)[n]2c3nc(Cl)nc(N)c3nc2)[C@H]1O Chemical compound C[C@](CO)(CC([C@@H]1O)[n]2c3nc(Cl)nc(N)c3nc2)[C@H]1O DJUSWOSTDQSFPL-NQALCROSSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- YOAHKNVSNCMZGQ-XPWFQUROSA-N P(1),P(4)-bis(5'-adenosyl) tetraphosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 YOAHKNVSNCMZGQ-XPWFQUROSA-N 0.000 description 1
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- WJDVSMBTIILRAJ-XEMBYONJSA-N [(1r,2r,3s,4r,5s)-4-(6-amino-2-methylsulfanylpurin-9-yl)-2,3-dihydroxy-1-bicyclo[3.1.0]hexanyl]methyl phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@H]1[C@H](O)[C@H](O)[C@]2(COP(O)(=O)OP(O)(O)=O)C[C@@H]21 WJDVSMBTIILRAJ-XEMBYONJSA-N 0.000 description 1
- NMVWLEUONAKGCD-SMWKGLLFSA-N [(1r,2s,4s,5s)-4-[2-iodo-6-(methylamino)purin-9-yl]-2-phosphonooxy-1-bicyclo[3.1.0]hexanyl]methyl dihydrogen phosphate Chemical compound CNC1=NC(I)=NC2=C1N=CN2[C@@H]1[C@H]2C[C@@]2(COP(O)(O)=O)[C@@H](OP(O)(O)=O)C1 NMVWLEUONAKGCD-SMWKGLLFSA-N 0.000 description 1
- HVOVBTNCGADRTH-WBLDMZOZSA-N [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-2-[[hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl]oxymethyl]oxolan-3-yl] 4-benzoylbenzoate;n,n-diethylethanamine Chemical compound CCN(CC)CC.O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 HVOVBTNCGADRTH-WBLDMZOZSA-N 0.000 description 1
- UWTUUIWWVPWHAA-XVFCMESISA-N [[(2r,3s,4r,5r)-4-amino-3-hydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=S)NC(=O)C=C1 UWTUUIWWVPWHAA-XVFCMESISA-N 0.000 description 1
- XNOBOKJVOTYSJV-KQYNXXCUSA-N [[(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XNOBOKJVOTYSJV-KQYNXXCUSA-N 0.000 description 1
- FIZCPSOYGRAJHH-LAJHJGSGSA-N [[(3ar,4r,6r,6ar)-2-benzyl-4-(2,4-dioxopyrimidin-1-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methoxy-hydroxyphosphoryl] [[(2s,3r,4s,5s)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound O([C@H]1[C@@H](O[C@@H]([C@H]1O1)COP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(NC(=O)C=C2)=O)O)O)N2C(NC(=O)C=C2)=O)C1CC1=CC=CC=C1 FIZCPSOYGRAJHH-LAJHJGSGSA-N 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- GAQWEBYIOMWWHZ-ZJWYQBPBSA-N azane;[(2r,3s,5r)-5-[6-(methylamino)purin-9-yl]-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound [NH4+].[NH4+].C1=NC=2C(NC)=NC=NC=2N1[C@H]1C[C@H](OP(O)([O-])=O)[C@@H](COP(O)([O-])=O)O1 GAQWEBYIOMWWHZ-ZJWYQBPBSA-N 0.000 description 1
- QTPILKSJIOLICA-UHFFFAOYSA-N bis[hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O QTPILKSJIOLICA-UHFFFAOYSA-N 0.000 description 1
- DUDALCZPYHIGIR-XVFCMESISA-N dihydroxyphosphinothioyl [[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=O)C=C1 DUDALCZPYHIGIR-XVFCMESISA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical class C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229950003529 diquafosol Drugs 0.000 description 1
- ZQKVPFKBNNAXCE-WFIJOQBCSA-L disodium;[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate;hydron Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP(O)([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 ZQKVPFKBNNAXCE-WFIJOQBCSA-L 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- PASYJVRFGUDDEW-WMUGRWSXSA-J tetrasodium;[[(2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)[C@@H](O)C1 PASYJVRFGUDDEW-WMUGRWSXSA-J 0.000 description 1
- FLEWBBDBZCYDHP-WHEJUCFXSA-J tetrasodium;[[[(2r,3r,4r,5r)-5-(6-amino-2-methylpurin-9-yl)-3-hydroxy-4-sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].C12=NC(C)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1S FLEWBBDBZCYDHP-WHEJUCFXSA-J 0.000 description 1
- QCBCNKBBEOQRRB-ODQFIEKDSA-J tetrasodium;[[[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].O1[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=S)NC(=O)C=C1 QCBCNKBBEOQRRB-ODQFIEKDSA-J 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- CBAGKCWFSRTVER-LRKXSUKJSA-K trisodium [(2R,3S,4S,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[[hydroxy(oxido)phosphoryl]oxy-oxidophosphoryl]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)CP([O-])(=O)OP(O)([O-])=O)[C@@H](O)[C@@H]1O CBAGKCWFSRTVER-LRKXSUKJSA-K 0.000 description 1
- DYNGCIHMNWOBSU-MSQVLRTGSA-K trisodium;[[(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical class [Na+].[Na+].[Na+].C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O DYNGCIHMNWOBSU-MSQVLRTGSA-K 0.000 description 1
- AUFUWRKPQLGTGF-FMKGYKFTSA-N uridine triacetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=C1 AUFUWRKPQLGTGF-FMKGYKFTSA-N 0.000 description 1
- CAWZRIXWFRFUQB-IOSLPCCCSA-N α,β Methylene ATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)CP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CAWZRIXWFRFUQB-IOSLPCCCSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022063285A JP7709141B2 (ja) | 2016-04-21 | 2022-04-06 | 神経学的状態および心血管状態を処置するための化合物および方法 |
| JP2025031851A JP2025084908A (ja) | 2016-04-21 | 2025-02-28 | 神経学的状態および心血管状態を処置するための化合物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325860P | 2016-04-21 | 2016-04-21 | |
| US62/325,860 | 2016-04-21 | ||
| PCT/US2017/028996 WO2017185061A1 (en) | 2016-04-21 | 2017-04-21 | Compounds and methods for treating neurological and cardiovascular conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063285A Division JP7709141B2 (ja) | 2016-04-21 | 2022-04-06 | 神経学的状態および心血管状態を処置するための化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515920A JP2019515920A (ja) | 2019-06-13 |
| JP2019515920A5 true JP2019515920A5 (enExample) | 2020-05-28 |
| JP7109005B2 JP7109005B2 (ja) | 2022-07-29 |
Family
ID=60022855
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555672A Active JP7109005B2 (ja) | 2016-04-21 | 2017-04-21 | 神経学的状態および心血管状態を処置するための化合物および方法 |
| JP2022063285A Active JP7709141B2 (ja) | 2016-04-21 | 2022-04-06 | 神経学的状態および心血管状態を処置するための化合物および方法 |
| JP2025031851A Pending JP2025084908A (ja) | 2016-04-21 | 2025-02-28 | 神経学的状態および心血管状態を処置するための化合物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063285A Active JP7709141B2 (ja) | 2016-04-21 | 2022-04-06 | 神経学的状態および心血管状態を処置するための化合物および方法 |
| JP2025031851A Pending JP2025084908A (ja) | 2016-04-21 | 2025-02-28 | 神経学的状態および心血管状態を処置するための化合物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US12239654B2 (enExample) |
| EP (2) | EP3445368B1 (enExample) |
| JP (3) | JP7109005B2 (enExample) |
| KR (2) | KR20220132042A (enExample) |
| CN (2) | CN109310695B (enExample) |
| AU (2) | AU2017254720B2 (enExample) |
| CA (1) | CA3020490A1 (enExample) |
| EA (1) | EA201892008A1 (enExample) |
| ES (1) | ES2989621T3 (enExample) |
| IL (2) | IL289423B2 (enExample) |
| MX (1) | MX391725B (enExample) |
| WO (1) | WO2017185061A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA120628C2 (uk) | 2014-11-07 | 2020-01-10 | Басф Се | Пестицидні суміші |
| US11241012B2 (en) | 2016-03-16 | 2022-02-08 | Basf Se | Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean |
| CA3015456C (en) | 2016-03-16 | 2024-09-17 | Basf Se | USE OF TETRAZOLINONES TO CONTROL RESISTANT PLANT PATHOGENIC FUNGI ON FRUIT |
| ES3056157T3 (en) | 2016-03-16 | 2026-02-18 | Basf Se | Use of a specific tetrazolinone for combating resistant phytopathogenic fungi on cereals |
| EP3445368B1 (en) | 2016-04-21 | 2024-07-17 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
| CN112218638A (zh) * | 2018-02-09 | 2021-01-12 | 阿斯特罗赛特制药公司 | 用于治疗成瘾和相关病症的化合物和方法 |
| WO2019232554A2 (en) * | 2018-05-26 | 2019-12-05 | Primetime Life Sciences, Llc | Compounds and methods for modulation of g-protein-coupled receptors |
| WO2020061211A1 (en) * | 2018-09-18 | 2020-03-26 | Saint Louis University | Use of highly-selective adenosine 3a receptor subtype agonists |
| EP3856741A4 (en) | 2018-09-26 | 2022-06-22 | Astrocyte Pharmaceuticals, Inc. | POLYMORPHOUS COMPOUNDS AND USES THEREOF |
| JP7282324B2 (ja) * | 2018-12-11 | 2023-05-29 | 株式会社島津製作所 | イオン化装置、質量分析装置および流体試料の分析方法 |
| WO2020176544A1 (en) * | 2019-02-25 | 2020-09-03 | Saint Louis University | Treatment of alzheimer's disease |
| JOP20210296A1 (ar) * | 2019-05-06 | 2023-01-30 | Ferrer Int | صور جرعة صلبة صيدلية أو دوائية مغذية متعددة الطبقات ومشتملة على مشتقات بيريميدين و/أو بيورين وفيتامينات ب، وتحضيرها واستخداماتها |
| IL307967A (en) * | 2021-04-28 | 2023-12-01 | Astrocyte Pharmaceuticals Inc | Purine nucleosides, their intermediates and methods for their preparation |
| KR20240122782A (ko) * | 2021-11-22 | 2024-08-13 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경학적 및 심혈관 상태를 치료하는 방법 |
| CA3250090A1 (en) * | 2022-02-10 | 2023-08-17 | Academia Sinica | METHOD FOR TREATMENT OF A SPINAL CORD INJURY AND CORRESPONDING COMPOSITION |
| WO2024097387A1 (en) * | 2022-11-03 | 2024-05-10 | Astrocyte Pharmaceuticals, Inc. | Compositions for intravenous administration |
| WO2024144874A2 (en) * | 2022-11-03 | 2024-07-04 | Astrocyte Pharmaceuticals, Inc. | Fast-dissolving dosage forms and uses thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995002604A1 (en) | 1993-07-13 | 1995-01-26 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| US7348315B2 (en) | 1995-03-23 | 2008-03-25 | The University Of Connecticut | Methods of treating heart failure with modified ATP, ADP and AMP compounds |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| US6586413B2 (en) | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| EP1248869A2 (en) | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US7087589B2 (en) | 2000-01-14 | 2006-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methanocarba cycloakyl nucleoside analogues |
| US7589075B2 (en) | 2001-01-16 | 2009-09-15 | Can-Fite Biopharma Ltd. | Use of an adenosine A3 receptor agonist for inhibition of viral replication |
| WO2003051881A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| GB0209539D0 (en) | 2002-04-26 | 2002-06-05 | Avecia Ltd | Monomer Polymer and process |
| EP2410332A1 (en) | 2002-11-21 | 2012-01-25 | The University Of Utah | Method for identifying purinergic modulators of the olfactory system |
| JP2007517019A (ja) * | 2003-12-29 | 2007-06-28 | カン−フィテ・バイオファーマ・リミテッド | 多発性硬化症の治療方法 |
| GB0405009D0 (en) * | 2004-03-05 | 2004-04-07 | Cambridge Biotechnology Ltd | Analgesics |
| JP2008512457A (ja) | 2004-09-09 | 2008-04-24 | アメリカ合衆国 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| WO2007020018A1 (en) | 2005-08-12 | 2007-02-22 | Universite Libre De Bruxelles | Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
| EP2049127B1 (en) | 2006-05-23 | 2014-11-26 | University of Connecticut | N-methanocarba derivatives to treat cardiac diseases |
| WO2008021552A2 (en) | 2006-08-18 | 2008-02-21 | Duke University | Biased ligands and methods of identifying same |
| US20100047798A1 (en) | 2006-11-08 | 2010-02-25 | Thomas Jefferson University | Adenosine a1 and a3 receptor gene sequence variations for predicting disease outcome and treatment outcome |
| US7867983B2 (en) | 2007-03-29 | 2011-01-11 | The University Of Connecticut | Methods to protect skeletal muscle against injury |
| US20090088403A1 (en) | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
| WO2009010871A2 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as antagonists of adenosine a3 receptor |
| DE102007055529A1 (de) | 2007-08-06 | 2009-02-12 | Rhode & Schwarz Gmbh & Co. Kg | Verfahren und Anordnung zum Erzeugen eines frequenzmodulierten Signals |
| JP5592262B2 (ja) | 2007-10-15 | 2014-09-17 | キャン−ファイト・バイオファーマ・リミテッド | 肝細胞の増殖を誘導する方法及びその使用 |
| BRPI0818578A2 (pt) | 2007-10-17 | 2015-07-21 | Novartis Ag | Derivados de purina como ligantes receptores de adenosina a1 |
| CN101925610A (zh) | 2007-11-23 | 2010-12-22 | 巴尔-伊兰大学 | 不可水解的二磷酸核苷或三磷酸核苷衍生物及其用途 |
| AU2009231978C1 (en) | 2008-03-31 | 2014-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as A3 adenosine receptor- selective agonists |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| EP2331542B1 (en) | 2008-08-01 | 2016-07-27 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | A3 adenosine receptor antagonists and partial agonists |
| US8685372B2 (en) | 2009-04-15 | 2014-04-01 | The Regents Of The University Of California | Peptides and aptamers for targeting of neuron or nerves |
| US8518957B2 (en) | 2009-12-02 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure |
| WO2011077435A1 (en) | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
| US8822434B2 (en) | 2010-02-22 | 2014-09-02 | The University Of Connecticut | Compositions and methods to treat cardiac diseases |
| US8691775B2 (en) | 2010-04-19 | 2014-04-08 | Back Bay Scientific, Llc | Use of drugs that activate P2Y receptors to enhance synaptogenesis |
| US9132131B2 (en) | 2011-04-21 | 2015-09-15 | Saint Louis University | Use of adenosine A3 receptor agonists for treatment of neuropathic pain |
| US20140241990A1 (en) | 2011-09-30 | 2014-08-28 | Tufts University | Methods of using adenosine a1 receptor activation for treating depression |
| SI2968385T1 (sl) | 2013-03-13 | 2018-10-30 | Tufts University | Uridin nukleozid derivati, sestavki in metode uporabe |
| US20150087613A1 (en) | 2013-09-26 | 2015-03-26 | Saint Louis University | Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy |
| US9963450B2 (en) | 2013-11-27 | 2018-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| US20160024135A1 (en) | 2014-07-27 | 2016-01-28 | Zhejiang Subtropical Crops Research Institute | Adenosine receptor activation reagent and the uses of thereof |
| HK1247119A1 (zh) | 2015-02-04 | 2018-09-21 | 贝克心脏与糖尿病研究所 | 一种治疗方法和用於所述治疗方法中的化合物 |
| RU2017129539A (ru) | 2015-02-24 | 2019-03-25 | Гальвани Байоэлектроникс Лимитед | Устройство нейромодуляции |
| CN108685935B (zh) * | 2015-05-06 | 2019-10-11 | 浙江省亚热带作物研究所 | 一种含有腺苷受体激动试剂的食品 |
| EP3445368B1 (en) | 2016-04-21 | 2024-07-17 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
| US10683292B2 (en) | 2016-07-25 | 2020-06-16 | Nerviano Medical Sciences S.R.L. | Purine and 3-deazapurine analogues as choline kinase inhibitors |
| CN109666053A (zh) * | 2017-10-16 | 2019-04-23 | 张家口华健致远生物科技有限公司 | 一种a3腺苷受体激动剂及其用途 |
| CN112218638A (zh) | 2018-02-09 | 2021-01-12 | 阿斯特罗赛特制药公司 | 用于治疗成瘾和相关病症的化合物和方法 |
| KR102602990B1 (ko) | 2018-06-27 | 2023-11-17 | 에스케이하이닉스 주식회사 | 전원 공급 장치 및 이를 포함하는 전자 장치 |
| EP3856741A4 (en) | 2018-09-26 | 2022-06-22 | Astrocyte Pharmaceuticals, Inc. | POLYMORPHOUS COMPOUNDS AND USES THEREOF |
| CA3146679A1 (en) | 2019-07-27 | 2021-02-04 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| IL307967A (en) | 2021-04-28 | 2023-12-01 | Astrocyte Pharmaceuticals Inc | Purine nucleosides, their intermediates and methods for their preparation |
| KR20240122782A (ko) | 2021-11-22 | 2024-08-13 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경학적 및 심혈관 상태를 치료하는 방법 |
-
2017
- 2017-04-21 EP EP17786774.4A patent/EP3445368B1/en active Active
- 2017-04-21 KR KR1020227032219A patent/KR20220132042A/ko not_active Ceased
- 2017-04-21 ES ES17786774T patent/ES2989621T3/es active Active
- 2017-04-21 CN CN201780024816.XA patent/CN109310695B/zh active Active
- 2017-04-21 US US16/095,282 patent/US12239654B2/en active Active
- 2017-04-21 JP JP2018555672A patent/JP7109005B2/ja active Active
- 2017-04-21 AU AU2017254720A patent/AU2017254720B2/en active Active
- 2017-04-21 CN CN202210281874.3A patent/CN114903903A/zh active Pending
- 2017-04-21 MX MX2018012655A patent/MX391725B/es unknown
- 2017-04-21 EA EA201892008A patent/EA201892008A1/ru unknown
- 2017-04-21 CA CA3020490A patent/CA3020490A1/en active Pending
- 2017-04-21 WO PCT/US2017/028996 patent/WO2017185061A1/en not_active Ceased
- 2017-04-21 IL IL289423A patent/IL289423B2/en unknown
- 2017-04-21 US US15/494,407 patent/US9789131B1/en active Active
- 2017-04-21 EP EP24184468.7A patent/EP4414027A3/en active Pending
- 2017-04-21 KR KR1020187033797A patent/KR102445887B1/ko active Active
- 2017-08-07 US US15/670,738 patent/US10265338B2/en active Active
-
2018
- 2018-10-21 IL IL262487A patent/IL262487B/en unknown
-
2019
- 2019-03-14 US US16/353,737 patent/US10953031B2/en active Active
-
2021
- 2021-02-19 US US17/180,469 patent/US11484545B2/en active Active
-
2022
- 2022-04-06 JP JP2022063285A patent/JP7709141B2/ja active Active
- 2022-09-21 US US17/934,169 patent/US12390483B2/en active Active
-
2023
- 2023-05-02 AU AU2023202694A patent/AU2023202694B2/en active Active
-
2025
- 2025-02-28 JP JP2025031851A patent/JP2025084908A/ja active Pending
- 2025-07-17 US US19/272,745 patent/US20250345353A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515920A5 (enExample) | ||
| JP7709141B2 (ja) | 神経学的状態および心血管状態を処置するための化合物および方法 | |
| JP2022088642A5 (enExample) | ||
| JP2016528891A5 (enExample) | ||
| JP2011520845A (ja) | 抗癌剤の組合せによる治療 | |
| JP7173613B2 (ja) | 多標的ヌクレオシド誘導体 | |
| KR20210148987A (ko) | 압타머 기반 표적화 복합 항암제 | |
| JP6431520B2 (ja) | フッ化ピリミジン類縁体及びその使用方法 | |
| WO2021202669A3 (en) | Nucleoside and nucleotide conjugate compounds and uses thereof | |
| HK40114882A (en) | Compounds and methods for treating neurological and cardiovascular conditions | |
| Parabucki et al. | Expression of major ectonucleotidases after cortical stab brain injury in rats: a real-time PCR study | |
| Lindley et al. | Presumptive Evidence for ADAR1 A-to-I Deamination at WA-sites as the Mutagenic Genomic Driver in | |
| EA047947B1 (ru) | Соединения и способы лечения неврологических и сердечно-сосудистых состояний | |
| BR112018071560B1 (pt) | Usos de um agonista para tratar condições neurológicas e cardiovasculares | |
| BR122024020857A2 (pt) | Usos de um agonista para tratar condições neurológicas e cardiovasculares | |
| HK40004057A (en) | Compounds and methods for treating neurological and cardiovascular conditions | |
| HK40004057B (en) | Compounds and methods for treating neurological and cardiovascular conditions | |
| NZ764110B2 (en) | Compositions and methods for modulating pkk expression | |
| NZ753783B2 (en) | Modified oligonucleotides for treatment of polycystic kidney disease |